Key result
The TRANSITION-CHD trial will evaluate whether a structured transition education program improves health-related quality of life over 12 months compared to standard care in 200 adolescents and young adults with congenital heart disease.
Why the study?
Many congenital heart disease patients are lost to follow-up during transition to adult care, and the level of evidence for therapeutic education programs remains low.
Does a transition education program improve health-related quality of life in adolescents and young adults with congenital heart disease?
RCT (n=200)
Open-label
1:1 ratio, stratified by age group
Yes
Does a transition education program improve health-related quality of life in adolescents and young adults with congenital heart disease?
This study protocol outlines a randomized controlled trial to evaluate the impact of a transition education program on the health-related quality of life of adolescents and young adults with congenital heart disease.
BACKGROUND: Recent advances in the field of congenital heart disease (CHD) led to an improved prognosis of the patients and in consequence the growth of a new population: the grown up with congenital heart disease. Until recently, more than 50% of these patients were lost to follow up because of the lack of specialized structures. The critical moment is the transition between paediatric and adult unit. Therapeutic education is crucial to solve this issue by helping patients to become independent and responsible. The TRANSITION-CHD randomized trial aims to assess the impact of a transition education program on health-related quality of life (HRQoL) of adolescents and young adults with CHD. METHODS: Multicentre, randomised, controlled, parallel arm study in CHD patients aged from 13 to 25 years old. Patients will be randomised into 2 groups (education program vs. no intervention). The primary outcome is the change in self-reported HRQoL between baseline and 12-month follow-up. A total of 100 patients in each group is required to observe a significant increase of the overall HRQoL score of 7 ± 13.5 points (on 100) with a power of 80% and an alpha risk of 5%. The secondary outcomes are: clinical outcomes, cardiopulmonary exercise test parameters (peak VO2, VAT, VE/VCO2 slope), level of knowledge of the disease using the Leuven knowledge questionnaire for CHD, physical and psychological status. DISCUSSION: As the current research is opening on patient related outcomes, and as the level of proof in therapeutic education is still low, we sought to assess the efficacy of a therapeutic education program on HRQoL of CHD patients with a randomized trial. TRIAL REGISTRATION: This study was approved by the National Ethics Committee (South-Mediterranean IV 2016-A01681-50) and was registered on Clinicaltrials.gov (NCT03005626).
No takes yet. Share an insight, caveat, or question.
Werner et al. (2021) conducted an RCT in Congenital heart disease (n=200). Transition education program vs. Regular non-modified follow-up (no formalized transition education program) was evaluated on Change in self-reported HRQoL (PedsQL score) between baseline and 12-month follow-up. The TRANSITION-CHD trial will evaluate whether a structured transition education program improves health-related quality of life over 12 months compared to standard care in 200 adolescents and young adults with congenital heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: